Project Grant R33CA263705
Award Date
9/23/21
Completion Date
8/31/25
Dollars Obligated
$4.6M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This National Institutes of Health National Cancer Institute project grant of $4.36M will enhance the University of California Santa Cruz XENA Browser to visualize single cell cancer data from the 21st Century Cures Act Beau Biden Cancer Moonshot initiative. Under the grant, UCSC will collaborate with two Cancer Moonshot projects to develop novel visualizations for single cell cancer data to elucidate changes in tumors and their microenvironments in response to therapy. UCSC will work with the...
This Project Grant award, in the amount of $1,131,820.00, was provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The award supports a research project titled "Symptomatic Toxicities & Quality of Life among Diverse Individuals Receiving Immune Checkpoint Inhibitors for Metastatic Cancer." The key objectives of this project are to: 1) characterize toxicities and health-related quality of life over...
The University of California, San Francisco (UCSF) received a $1,019,013 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The overarching goal of this 5-year project is to develop a pre-cancer atlas of skin cancer, with a focus on melanoma and cutaneous squamous cell carcinoma, to understand the genetic and immunological events that occur during the transition from pre-cancer to cancer. The...
This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...
The President and Fellows of Harvard College, doing business as Harvard Medical School, was awarded a $4,597,818 project grant from the National Cancer Institute within the Department of Health and Human Services. The grant is funded under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), which supports cancer research initiatives. Under this award, Harvard Medical School will develop an integrative visualization framework for spatial single-cell cancer datasets...
This $680,334 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research at the Icahn School of Medicine at Mount Sinai to elucidate the molecular mechanisms driving age-associated pro-tumoral myelopoiesis, a key factor contributing to increased cancer risk and progression in the elderly. The research aims to identify the specific cellular players and signaling pathways involved in the age-related inflammatory response, characterize the...
The Icahn School of Medicine at Mount Sinai will receive $1,420,835 under a three-year Project Grant from the Defense Health Agency to target the immunosuppressive microenvironment of prostate cancer and enhance the therapeutic efficacy of immune checkpoint inhibitors. The grant, awarded June 1, 2023 under the Military Medical Research and Development program (CFDA 12.420), will support basic, applied, and advanced biomedical research aimed at transforming health care for service members and the...
This $2,372,456 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports a collaborative effort led by the Sloan-Kettering Institute For Cancer Research to leverage observational (real-world) data to advance precision oncology. The key projects under this P01 program include: Overcoming methodological barriers in analyzing observational clinico-genomic data, with sub-awards to Dana-Farber Cancer Institute and University of California,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai is for the development and optimization of a scalable, cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ) that jointly captures gene expression, chromatin accessibility, and DNA methylation. The goal is to apply this new technique to identify and target methylation-driven pathways in acute myeloid leukemia (AML). The...
This $811,500 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will fund the development of a comprehensive platform for patient-specific mechanistic tumor modeling. The key products and services to be delivered include: Merging bioinformatics software for single-cell and spatial multi-omics data analysis with an agent-based modeling framework (PhysiCell) to simulate cell movement and interactions in virtual tissue environments. This will be...